<DOC>
	<DOCNO>NCT00504881</DOCNO>
	<brief_summary>This study compare safety efficacy Brivaracetam flexible dose Placebo subject suffer Epilepsy .</brief_summary>
	<brief_title>Brivaracetam add-on Treatment Adolescents Adults Suffering From Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subjects age 16 70 year , inclusive . Subjects 18 year age include legally permit ethically accepted Subjects wellcharacterized localizationrelated Epilepsy generalize Epilepsy accord International League Against Epilepsy ( ILAE ) classification For subject suffer localizationrelated Epilepsy : subject least 2 PartialOnset Seizures ( POSs ) whether secondarily generalize per month 3 month precede Visit 1 accord ILAE classification For subject suffer localizationrelated Epilepsy : subject least 4 PartialOnset Seizures ( POSs ) whether secondarily generalize 4week Baseline Period accord ILAE classification For subject suffer generalized Epilepsy : subject least 2 Type IIseizure day per month 3 month precede Visit 1 accord ILAE classification For subject suffer generalized Epilepsy : subject least 4 Type IIseizure day 4 week Baseline Period accord ILAE classification Subjects uncontrolled treat 1 3 permit concomitant Antiepileptic Drugs ( AEDs ) . Vagal nerve stimulation allow count concomitant AED For subject suffer localizationrelated Epilepsy : history presence Seizures occur cluster ( frequently indistinctly separate reliably count ) Visit 2 occur Type IA nonmotor Subjects history presence Status Epilepticus year precede Visit 1 Baseline</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Partial Onset Seizures</keyword>
</DOC>